FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035250214> ?p ?o ?g. }

• W2035250214 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAIntroduction: c-Myc plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression and its overexpression is associated with aggressiveness and poor prognosis in many cancers. Three celastrol analogues, SBI 064601(601), SBI 0640599(599) and SBI 0069272(272) are potent c-Myc inhibitors. We have evaluated the ability of these celastrol analogues to inhibit Daudi lymphoma cells in vitro and in vivo and characterized the pharmacokinetics of these celastrol analogues in C.B-17 SCID mice bearing Daudi xenografts.Methods: Inhibition of Daudi cell growth by three celastrol analogues was assessed by MTT assay after 72 h of incubation. For the efficacy study, the mice bearing Daudi xenografts were treated with 20 mg/kg iv of 601, 599, 272 qdx5, or with 50 mg/kg of 601(iv) and 272 (iv and po), respectively on a qdx5 for two weeks schedule. For pharmacokinetic studies, the mice were administered all three analogues iv at 20 mg/kg and 272 was also given at 50 mg/kg iv and po. Plasma and tissues were collected between 5 and 1440 min. Concentrations of the analogues were determined by LC-MS/MS and non-compartmental analysis was performed using PK solutions.Results: The IC50's of 601, 599 and 272 against Daudi cells in vitro were 2.9 µM, 25.4 µM and 10.6 µM, respectively. The mean tumor time to two doublings for 601, 599 or 272 at 20 mg/kg iv were 16.5±0.9 , 12.7±3.3 and 14.5±3.8 days, respectively, compared with control (11.7±3.9 days). At 50 mg/kg, the mean tumor time to two doublings for 601(iv), or 272 (iv or po) were 10.7±6.0, 6.7±2.6 and 5.3±1.6 days, respectively, compared with control (7.1±2.9 days). Following a single iv dose with 20 mg/kg of the analogues or 50 mg/kg of 272, plasma and tumor Cmax occurred at 5 min. Plasma and tumor Cmax occurred at 30 min for 272 po. AUC0-t for 601, 599 and 272 at 20 mg/kg iv were 1219, 5417, and 9411 µg•min/ml, respectively. AUC0-t for 272 at 50 mg/kg iv and po were 21908 and 7184 µg•min/ml, respectively. Plasma t1/2 of 601, 599 and 272 at 20 mg/kg iv were approximately 165, 38, and 454 min respectively. Plasma t1/2 of 272 at 50 mg/kg iv or po were 763 and 239 min, respectively. Clearances for 601, 599 at 20 mg/kg iv and 272 at 50 mg/kg iv or po in plasma were 15.3, 3.7, 2.1, 2.5 and 7.0 ml/min/kg, respectively.Conclusion: 601 had the lowest IC50 against Daudi cells in vitro and resulted in a significant delay in tumor time to two doublings after 20 mg/kg iv. There were no significant effects of the other celastrol analogues on Daudi lymphoma growth in vivo at 20 mg/kg and 50 mg/kg iv or po. 601 is under further preclinical evaluation against other human tumor xenografts.Support: R01-CA078039 and P30-CA47904Citation Format: Jianxia Guo, Kathleen Paul, Edward V. Prochownik, Nicholas Cosford, Robert A. Parise, Jan H. Beumer, Julie L. Eiseman. Efficacy, pharmacokinetics and tissue distribution of celastrol analogues SBI 064601, SBI 0640599 and SBI 0069272 in C.B-17 SCID mice bearing Daudi Burkitt's lymphoma xenografts. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4644. doi:10.1158/1538-7445.AM2014-4644" @default.
• W2035250214 created "2016-06-24" @default.
• W2035250214 creator A5025873983 @default.
• W2035250214 creator A5027371881 @default.
• W2035250214 creator A5027998409 @default.
• W2035250214 creator A5039016268 @default.
• W2035250214 creator A5070200212 @default.
• W2035250214 creator A5077511890 @default.
• W2035250214 creator A5086726605 @default.
• W2035250214 date "2014-09-30" @default.
• W2035250214 modified "2023-09-29" @default.
• W2035250214 title "Abstract 4644: Efficacy, pharmacokinetics and tissue distribution of celastrol analogues SBI 064601, SBI 0640599 and SBI 0069272 in C.B-17 SCID mice bearing Daudi Burkitt's lymphoma xenografts" @default.
• W2035250214 doi "https://doi.org/10.1158/1538-7445.am2014-4644" @default.
• W2035250214 hasPublicationYear "2014" @default.
• W2035250214 type Work @default.
• W2035250214 sameAs 2035250214 @default.
• W2035250214 citedByCount "0" @default.
• W2035250214 crossrefType "proceedings-article" @default.
• W2035250214 hasAuthorship W2035250214A5025873983 @default.
• W2035250214 hasAuthorship W2035250214A5027371881 @default.
• W2035250214 hasAuthorship W2035250214A5027998409 @default.
• W2035250214 hasAuthorship W2035250214A5039016268 @default.
• W2035250214 hasAuthorship W2035250214A5070200212 @default.
• W2035250214 hasAuthorship W2035250214A5077511890 @default.
• W2035250214 hasAuthorship W2035250214A5086726605 @default.
• W2035250214 hasConcept C112705442 @default.
• W2035250214 hasConcept C126322002 @default.
• W2035250214 hasConcept C150903083 @default.
• W2035250214 hasConcept C185592680 @default.
• W2035250214 hasConcept C190283241 @default.
• W2035250214 hasConcept C202751555 @default.
• W2035250214 hasConcept C207001950 @default.
• W2035250214 hasConcept C2777228702 @default.
• W2035250214 hasConcept C2777752497 @default.
• W2035250214 hasConcept C2779338263 @default.
• W2035250214 hasConcept C55493867 @default.
• W2035250214 hasConcept C71924100 @default.
• W2035250214 hasConcept C86803240 @default.
• W2035250214 hasConcept C98274493 @default.
• W2035250214 hasConceptScore W2035250214C112705442 @default.
• W2035250214 hasConceptScore W2035250214C126322002 @default.
• W2035250214 hasConceptScore W2035250214C150903083 @default.
• W2035250214 hasConceptScore W2035250214C185592680 @default.
• W2035250214 hasConceptScore W2035250214C190283241 @default.
• W2035250214 hasConceptScore W2035250214C202751555 @default.
• W2035250214 hasConceptScore W2035250214C207001950 @default.
• W2035250214 hasConceptScore W2035250214C2777228702 @default.
• W2035250214 hasConceptScore W2035250214C2777752497 @default.
• W2035250214 hasConceptScore W2035250214C2779338263 @default.
• W2035250214 hasConceptScore W2035250214C55493867 @default.
• W2035250214 hasConceptScore W2035250214C71924100 @default.
• W2035250214 hasConceptScore W2035250214C86803240 @default.
• W2035250214 hasConceptScore W2035250214C98274493 @default.
• W2035250214 hasLocation W20352502141 @default.
• W2035250214 hasOpenAccess W2035250214 @default.
• W2035250214 hasPrimaryLocation W20352502141 @default.
• W2035250214 hasRelatedWork W1562693843 @default.
• W2035250214 hasRelatedWork W2014105974 @default.
• W2035250214 hasRelatedWork W2046322471 @default.
• W2035250214 hasRelatedWork W2081325614 @default.
• W2035250214 hasRelatedWork W2269149596 @default.
• W2035250214 hasRelatedWork W2328569641 @default.
• W2035250214 hasRelatedWork W2328602479 @default.
• W2035250214 hasRelatedWork W2345512270 @default.
• W2035250214 hasRelatedWork W2359107428 @default.
• W2035250214 hasRelatedWork W2366271449 @default.
• W2035250214 hasRelatedWork W2366793750 @default.
• W2035250214 hasRelatedWork W2369764254 @default.
• W2035250214 hasRelatedWork W2370642444 @default.
• W2035250214 hasRelatedWork W2388762021 @default.
• W2035250214 hasRelatedWork W2418785451 @default.
• W2035250214 hasRelatedWork W2460843389 @default.
• W2035250214 hasRelatedWork W2559882666 @default.
• W2035250214 hasRelatedWork W3029203610 @default.
• W2035250214 hasRelatedWork W3032410844 @default.
• W2035250214 hasRelatedWork W3196228169 @default.
• W2035250214 isParatext "false" @default.
• W2035250214 isRetracted "false" @default.
• W2035250214 magId "2035250214" @default.
• W2035250214 workType "article" @default.